Delving into the Latest Updates on Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd with Synapse

Overview

Basic Info

Introduction

Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd. operates as a national high-tech company deeply involved in the research, development, manufacture, and commerce of biopharmaceutical technology and related products. This entity has marked its presence in the Zhejiang province as an organization dedicated to the development and manufacturing of microecological preparations. Established in December 2004, Hangzhou Longda Xinke has built itself upon the cultural tenets of loyalty, simplicity, diligence, and innovation.

Tags

Other Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

Probiotics

Enzyme

Live biotherapeutic products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Probiotics	2
Live biotherapeutic products	1
Enzyme	1

Top 5 Target	Count

UOX(urate oxidase (pseudogene))	1

主要目的： 1) 评价HZBio1在痛风受试者中多次给药的安全耐受性； 2) 评价HZBio1在痛风受试者中多次给药的药代动力学（PK）特征。次要目的： 1）初步评价HZBio1在痛风受试者中多次给药的药效动力学（PD）特征； 2）初步评价HZBio1在痛风受试者体内多次给药的免疫原性。

[Translation]

Main objectives: 1) To evaluate the safety and tolerability of multiple administration of HZBio1 in gout subjects; 2) To evaluate the pharmacokinetic (PK) characteristics of multiple doses of HZBio1 in gout subjects. Secondary objectives: 1) To preliminarily evaluate the pharmacodynamic (PD) characteristics of multiple doses of HZBio1 in gout subjects; 2) Preliminary evaluation of the immunogenicity of HZBio1 administered multiple times in gout subjects.

Start Date17 Nov 2022

Sponsor / Collaborator

Chongqing Paijin Biotechnology Co Ltd

[+1]

100 Clinical Results associated with Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd

Login to view more data

0 Patents (Medical) associated with Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd

Login to view more data

100 Deals associated with Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd

Login to view more data

100 Translational Medicine associated with Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

1

Phase 2 Clinical

Approved

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Clostridium Butyricum (Grand Life Science)	Acute diarrhea More	Approved
Pegylated recombinant uricase(Chongqing Paijin Biotechnology Co Ltd) ( UOX )	Gout More	Phase 2 Clinical
Combined Bifidobacterium ,Lactobacillus,Enterococcus And Bacillus (Grand Biologic)	Constipation - functional More	Phase 1
HZBio-2	Crohn Disease More	Phase 1